GLP-1 (Glucagon-Like Peptide-1) Biology

Glucagon-like peptide-1 (GLP-1) is the dominant incretin hormone in human physiology. The incretin concept originates from a simple observation: oral glucose provokes a substantially greater insulin response than the same glucose load delivered intravenously, even at matched plasma glucose levels. This amplification accounts for roughly 60-70% of postprandial insulin secretion and is mediated by two gut hormones, GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). GLP-1 is the more pharmacologically tractable of the two, and its receptor system has become the foundation of modern metabolic therapeutics.

Synthesis and processing

GLP-1 is encoded within the proglucagon gene (GCG), which produces a 160-amino-acid precursor expressed in pancreatic alpha cells, intestinal L-cells, and brainstem neurons. The same precursor yields different bioactive peptides depending on tissue, because different prohormone convertase enzymes perform the cleavage.

In intestinal L-cells, prohormone convertase 1/3 (PC1/3) cleaves proglucagon to release GLP-1, GLP-2, oxyntomodulin, and glicentin. In pancreatic alpha cells, prohormone convertase 2 (PC2) cleaves the same precursor to release glucagon. A single gene therefore serves opposing metabolic functions: glucagon raises blood glucose while GLP-1 lowers it. PC1/3 versus PC2 expression is the regulatory switch.

The biologically active forms are GLP-1(7-36)amide and GLP-1(7-37), with the amidated form predominating in circulation. The numbering reflects position within the full proglucagon sequence -- the first six residues are removed during processing.

GLP-1 receptor signaling

The GLP-1 receptor (GLP-1R) is a class B (secretin family) G-protein-coupled receptor. Its large extracellular domain provides initial peptide binding; the seven-transmembrane domain is where full agonist engagement triggers G-protein coupling.

The canonical Gs-cAMP pathway. GLP-1 binding activates Gs-alpha, stimulating adenylyl cyclase and raising intracellular cAMP. cAMP activates two parallel effectors: protein kinase A (PKA) and exchange protein directly activated by cAMP 2 (EPAC2). In beta cells, PKA and EPAC2 cooperatively close KATP channels, depolarizing the membrane and opening voltage-gated calcium channels. The resulting calcium influx drives insulin granule exocytosis.

This pathway is inherently glucose-dependent. At low blood glucose, KATP channels remain open and cAMP/PKA alone cannot reach the depolarization threshold. Insulin release occurs only when glucose metabolism has already partially closed KATP channels -- the safety advantage of GLP-1 receptor agonists over sulfonylureas.

Beta-arrestin and biased agonism. GLP-1R also recruits beta-arrestin-1 and beta-arrestin-2, mediating receptor internalization via clathrin-coated pits. Internalized complexes continue signaling from endosomes, activating ERK1/2 and pathways distinct from the plasma membrane Gs signal. Different agonists produce different G-protein versus beta-arrestin ratios -- biased agonism -- which may influence the balance of therapeutic effects to side effects such as nausea.

DPP-4 degradation

Native GLP-1 has a plasma half-life of approximately 2 minutes. Dipeptidyl peptidase-4 (DPP-4), a serine protease on endothelial surfaces and in soluble form, cleaves the N-terminal His7-Ala8 dipeptide to produce inactive GLP-1(9-36)amide. Most secreted GLP-1 is degraded before reaching systemic circulation.

Two therapeutic strategies emerged. DPP-4 inhibitors (sitagliptin, saxagliptin) block the enzyme, modestly raising endogenous GLP-1 two- to threefold. The more potent approach is DPP-4-resistant GLP-1 receptor agonists engineered to persist in circulation for hours to days.

Pleiotropic effects beyond insulin

GLP-1R is expressed well beyond the pancreas:

• Glucagon suppression -- inhibits alpha-cell glucagon secretion in a glucose-dependent manner, reducing hepatic glucose output while preserving counter-regulatory responses during hypoglycemia.
• Gastric emptying delay -- activates vagal afferents that slow gastric motility, flattening postprandial glucose excursions and contributing to satiety.
• Central satiety signaling -- GLP-1R in the hypothalamic arcuate and paraventricular nuclei, area postrema, and NTS mediates appetite suppression. The area postrema sits outside the blood-brain barrier, making it accessible to circulating agonists.
• Beta-cell preservation -- upregulates PDX-1 and activates anti-apoptotic pathways (PI3K/Akt, Bcl-2). Rodent models show increased beta-cell mass; human evidence suggests functional preservation.
• Cardiovascular effects -- GLP-1R on cardiomyocytes and endothelium mediates improved myocardial glucose uptake, nitric oxide production, and reduced vascular inflammation. The SELECT trial demonstrated 20% MACE reduction with semaglutide.
• Neurological effects -- GLP-1R in the hippocampus and mesolimbic dopamine system shows neuroprotective potential. Clinical trials of semaglutide in Alzheimer's and Parkinson's disease are ongoing.

Engineering long-acting analogs

The 2-minute native half-life required creative engineering to produce viable drugs:

Fatty acid acylation enables albumin binding, creating a circulating reservoir. Liraglutide uses a C16 fatty acid (half-life ~13 hours, daily dosing). Semaglutide uses a C18 fatty diacid with a mini-PEG spacer plus an Aib8 substitution to block DPP-4, achieving ~7-day half-life and weekly dosing.

Fc fusion -- dulaglutide fuses a GLP-1 analog to the IgG4 Fc domain, resisting renal filtration and recycling via FcRn for a ~5-day half-life.

Exendin-4 backbone -- exenatide uses a Gila monster venom peptide sharing 53% homology with human GLP-1 but naturally DPP-4 resistant (glycine at position 8 instead of alanine).

Dual GIP/GLP-1 agonism -- tirzepatide is built on a GIP-like backbone engineered to also activate GLP-1R, with C20 fatty diacid acylation for ~5-day half-life. GIP receptor activation enhances adipocyte lipid handling while GLP-1R drives insulin secretion and satiety. SURMOUNT-1 showed 22.5% weight reduction, exceeding selective GLP-1R agonists.

Clinical context

GLP-1 receptor agonists are first- or second-line therapies for type 2 diabetes with established cardiovascular benefit. In obesity, semaglutide and tirzepatide produce 15-22% weight loss, approaching bariatric surgery efficacy. Investigation extends to NASH, where semaglutide has reduced liver fibrosis markers, and to neurodegenerative diseases where GLP-1R's neuroprotective properties are being tested. The biology of GLP-1 -- a gut hormone with receptor expression across nearly every metabolic organ -- explains why its pharmacological exploitation has proven so broadly therapeutic.